Trial Profile
A Phase 1/2/3 Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs RGX 121 (Primary) ; RGX 121 (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions; First in man; Pharmacodynamics; Registrational
- Acronyms CAMPSIITE
- Sponsors REGENXBIO
- 07 Feb 2024 According to a REGENXBIO media release, following an RMAT meeting held with FDA at the end of 2023, REGENXBIO continues with plans to use CSF levels of D2S6 as a surrogate endpoint for accelerated approval and is completing remaining activities in order to file a BLA in the second half of 2024. Based on an expected priority review, potential approval of the planned BLA could result in receipt of a Rare Pediatric Disease Priority Review Voucher in 2025.
- 07 Feb 2024 According to a REGENXBIO media release, results from this trial were presented at the 20th Annual WORLDSymposium™ by Paul Harmatz, M.D., UCSF Benioff Children's Hospital and trial investigator.
- 07 Feb 2024 Topline results from this trial presented in a REGENXBIO media release.